Obesity is a multifaceted, escalating global health crisis, affecting over a billion people in 2022 and projected to impact more than half the adult population by 2050. As a chronic, relapsing, multifactorial disease, it increases the risk of serious non-communicable diseases (e.g., type 2 diabetes, cardiovascular diseases, certain cancers) and contributes to over 5 million deaths annually. The global economic burden is projected to reach $4.32 trillion by 2035, alongside psychosocial challenges such as stigma, low self-esteem, and social isolation.
For adults with a BMI ≥30 kg/m², or ≥27 kg/m² with at least one obesity-related comorbidity, pharmacologic therapy should be considered when lifestyle interventions alone fail to achieve ≥5% weight loss after 3–6 months. When paired with behavioral and lifestyle measures, long-acting, once-weekly GLP-1 receptor agonists have been associated with substantial, sustained weight loss (e.g., a mean 12.1% reduction in body weight) and improvements in BMI, waist circumference, and blood pressure.
Viewing obesity as a chronic disease means shifting from short-term fixes to long-term care strategies. Management should address genetic, metabolic, environmental, and social drivers while evaluating the impact of functional limitations and emotional factors—such as psychological distress, stigma, and disordered eating—that may compromise adherence. Personalized care, aligned to each patient’s clinical, functional, and psychosocial profile, is essential for durable outcomes.
How can functional and emotional burden assessments be systematically integrated into obesity care to improve adherence and outcomes? What strategies can HCPs use to embed these therapies into long-term care plans that integrate pharmacologic, behavioral, and lifestyle support?
• Adherence drivers: Tracking function, QoL, stigma, and eating symptoms surfaces the real barriers to taking meds and showing up. 
• Evidence-aligned meds: Long-acting, once-weekly incretin therapies produce the largest average losses with lifestyle support, and switching/intensifying when needed is guideline-concordant.